Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ATP4A | P20648 | 3/20 | 0.36 |
| ▸ | ATP4B | P51164 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1815255 | 1.00 | RET (0.36) | RETKDRATP4AATP4BCYP3A4 | |
| SCHEMBL4981356 | 0.83 | ATP4A (0.35) | ATP4AATP4BCYP3A4CYP2C9MEN1 | |
| SCHEMBL5557033 | 0.82 | ATP4A (0.34) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL5557163 | 0.81 | ATP4A (0.35) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL6487366 | 0.81 | ATP4A (0.35) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL5652760 | 0.81 | ATP4A (0.32) | ATP4AATP4BCYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL4733704 | 0.80 | L3MBTL1 (0.36) | ATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL4731646 | 0.79 | RET (0.36) | RETKDRCYP3A4CYP2C9MEN1 | |
| SCHEMBL1816326 | 0.79 | ATP4A (0.40) | ATP4AATP4BCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL4591400 | 0.79 | ATP4A (0.40) | ATP4AATP4BCYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008058990-A1 | 7,7-DISUBSTITUTED PYRANO-[2,3-C]-IMIDAZO-[1,2-A]-PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS | NYCOMED GMBH (DE) | 2008-05-22 | — | — | WO | disclosed |
| US-20080114020-A1 | such as 7,7-Difluoro-2,3-dimethyl-8-hydroxy-9-phenyl-7H-8,9-dihydro-pyrano(2,3-c]imidazo[1,2-a]pyridine; inhibit gastric acid secretion by blockade of the H+/K+-ATPase; reversible proton pump inhibitors (rPPI's) or acid pump antagonists (APA's) bind reversibly to H+/K+-ATPase; gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| EP-1286999-B1 | PYRANO[2,3-c]IMIDAZO[1,2-a]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | NYCOMED GMBH (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-6936623-B2 | Pyrano[2,3-C]imidazo[-1,2-A]pyridine derivatives for the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040180920-A1 | Pyrano[2,3-C]imidazo[-1,2-A]pyridine derivatives for the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2004-09-16 | — | — | US | disclosed |
| US-20030100578-A1 | Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2003-05-29 | — | — | US | disclosed |
| EP-1286999-A1 | PYRANO[2,3-c]IMIDAZO[1,2-a]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA Pharma AG (DE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001072755-A1 | PYRANO[2,3-C]IMIDAZO[-1,2-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA PHARMA AG (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100578-A1 | Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders | ALPI, GIPR, SLC10A2 | RET 2278/4885KDR 4865/4885ATP4A 618/4885 |
| US-20080114020-A1 | such as 7,7-Difluoro-2,3-dimethyl-8-hydroxy-9-phenyl-7H-8,9-dihydro-pyrano(2,3-c]imidazo[1,2-a]pyridine; inhibit gastric acid secretion by blockade of the H+/K+-ATPase; reversible proton pump inhibitors (rPPI's) or acid pump antagonists (APA's) bind reversibly to H+/K+-ATPase; gastrointestinal disorders | ATP6AP1, ATP1A1, ATP1A4 | RET 1455/4885KDR 4309/4885ATP4A 5/4885 |
| US-20040180920-A1 | Pyrano[2,3-C]imidazo[-1,2-A]pyridine derivatives for the treatment of gastrointestinal disorders | ALPI, GIPR, SLC10A2 | RET 2354/4885KDR 4865/4885ATP4A 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.